TIMI Investigators have studied a wide range of interventions including fibrinolytic, antiplatelet, anticoagulant, anti-ischemic, lipid-modifying, anti-inflammatory, anti-diabetes, and antiobesity agents, as well as percutaneous coronary intervention. Trials have ranged from less than 30 subjects to more than 26,000 subjects and have been conducted at more than 5,000 separate sites in 50 countries. Since that time, the TIMI Study Group has conducted more than 60 clinical trials spanning from phase I to phase IV studies. The trial was a success and demonstrated the superiority of tPA, which became the preferred fibrinolytic therapy. The first TIMI trial compared the effects of the then-new intravenously administered tissue plasminogen activator (tPA) with streptokinase on coronary and clinical outcomes in patients presenting with an ST-elevation myocardial infarction (STEMI). About the TIMI Study GroupĮstablished in 1984, the TIMI Study Group at BWH is the oldest cardiovascular Academic Research Organization (ARO) in North America and was led by Founding Chairman Eugene Braunwald, MD, until 2011. Although rates of TIMI major bleeding were higher with ticagrelor than with placebo, the rates of intracranial hemorrhage or fatal bleeding did not differ between the treatment and placebo groups. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke.Ĭompared with placebo, the two ticagrelor doses each reduced the rate of the primary efficacy end point at three years, with a 15 percent reduction with the 90 mg dose and a 16 percent reduction with the 60 mg dose (3-year event rate of 7.85 percent and 7.77 versus 9.04 percent) ( Figure 2). All patients received low-dose aspirin and were followed for a median of 33 months. The study randomized 21,162 patients who had a myocardial infarction one to three years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. In the PEGASUS-TIMI 54 study, researchers theorized that the addition of ticagrelor, a potent, reversibly-binding, direct acting P2Y12 antagonist, to standard therapy would reduce the incidence of major adverse cardiovascular events during long-term follow-up in patients with a history of myocardial infarction. Prolongation of P2Y12 Antagonist TherapyĬurrent guidelines recommend adding a P2Y12 receptor antagonist to aspirin only for the first year after an acute coronary syndrome. “The PCSK9 inhibitor data is remarkable and represent important findings that are helping open up a new era in lipid-lowering therapies,” said Jorge Plutzky, MD, Director of Preventive Cardiology. The first PCSK9 inhibitor was approved by the FDA at the end of July, with the second such agent being reviewed later this year. Sabatine spoke about evolocumab at the FDA Advisory Committee meeting, at the end of which the committee voted to recommend approval. The treatment appeared to be safe and well tolerated. The rate of cardiovascular events at one year was reduced by 53 percent, from 2.18 percent in the standard-therapy group to 0.95 percent in the evolocumab group ( Figure 1). Patients were followed for a median of 11.1 months.Īs compared with standard therapy alone, evolocumab reduced the level of LDL cholesterol by 61 percent, from a median of 120 mg per deciliter to 48 mg per deciliter. Extension studies (the OSLER program) were conducted from these parent trials in which 4,465 patients from 12 parent studies were randomly assigned in a 2:1 ratio to receive either evolocumab (140 mg every two weeks or 420 mg monthly) plus standard therapy or standard therapy alone. In previous short-term studies, evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels. “Our team is focused on conducting large-scale, practice changing clinical trials in patients with cardiovascular disease or risk factors for cardiovascular disease,” said Dr. In both studies the experimental therapy significantly reduced cardiovascular events in the studied patient populations. Sabatine, MD, MPH, Chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group and Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women’s Hospital (BWH), presented two late-breaking clinical trials. Results of Two Late-breaking Clinical Trials Presented by Brigham and Women’s Hospital TIMI Study Group at the American College of Cardiology Annual Scientific SessionĪt the 64th Annual Scientific Session of the American College of Cardiology (ACC), Marc S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |